Proteomics International Launches A$5 Million SPP to Fund Promarker Rollout and US Expansion

Sonal Goyal

04 November 2026 11:37 AM AEDT

Proteomics International Launches A$5 Million SPP to Fund Promarker Rollout and US Expansion

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Proteomics International Laboratories Ltd (ASX:PIQ) has launched a Share Purchase Plan to raise A$5 million, with the offer opening on 4 November 2026 and closing on 25 November 2026, according to an investor webinar presentation filed with the exchange on 4 November 2026.

Key Points

Share Purchase Plan launched to raise A$5 million, opening 4 November and closing 25 November 2026
Funds targeted to commercial execution and expected to support operations to October 2027
Healius secured as exclusive Australian pathology distributor with national rollout of Promarker D and Eso commenced
Independent validation of Promarker Endo completed; launch targeted for January–March 2027
Initial US distributor appointment targeted for the second half of FY27

Share Purchase Plan Details and Funding Target

The company disclosed that the Share Purchase Plan opened on 4 November 2026 and is scheduled to close on 25 November 2026, with a fundraising target of A$5 million. According to the filing, proceeds are targeted to commercial execution and are expected to support operations through to October 2027. The company also disclosed that it has reorganised its business and reduced operating costs as part of its commercial preparation.

Healius Partnership and Promarker Commercialisation

Proteomics International disclosed that it has secured Healius as its exclusive Australian pathology distributor and has commenced the national rollout of its Promarker D and Promarker Eso tests. Promarker D is described in the filing as a prognostic blood test to predict the risk of diabetes-related chronic kidney disease up to four years before symptoms appear. Promarker Eso is described as a diagnostic blood test for patients with chronic reflux that detects specific protein changes to rule out oesophageal adenocarcinoma. The company stated its commercial model is distributor-led, with a private-pay launch while reimbursement is being pursued in Australia.

Promarker Endo Validation and US Distribution Target

The filing states that the company has completed an independent validation of Promarker Endo, a diagnostic blood test for patients with symptoms suggestive of endometriosis. The company has targeted a launch of Promarker Endo in the January to March 2027 period. Additionally, the filing discloses a target to appoint an initial US distributor in the second half of FY27, alongside plans to advance reimbursement in both Australia and the United States and to improve laboratory efficiency and capacity. The company operates accredited NATA laboratory facilities in Australia and holds CLIA/CAP laboratory capability in the US.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.